PRINCETON, N.J., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previously-disclosed acquisition of ACell, Inc.

“Acquiring ACell and its proprietary MatriStem UBM™ technologies will enable Integra to provide more comprehensive complex wound management solutions to address our customers’ most pressing clinical challenges,” said Peter Arduini, president and CEO, Integra LifeSciences. “Together with ACell colleagues, we look forward to continuing to advance wound care innovations for our customers and patients.”

Sullivan & Cromwell LLP is acting as legal advisor to Integra.

About Integra LifeSciences

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel^®, Bactiseal^®, Cerebroflo^®, Certas^® Plus, Codman^®, CUSA^®, DuraGen^®, DuraSeal^®, ICP Express^®, Integra^®, MediHoney^®, MicroFrance^®, PriMatrix^®, SurgiMend^®, TCC-EZ^®, and VersaTru™. For the latest news and information about Integra and its products, please visit www.integralife.com.